Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)?

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 4, 2009, Pages 509-515

  Rowe, Jacob M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

AML; anthracyclines; ara C; cytarabine; daunorubicin; induction; intensification

Indexed keywords

ACLARUBICIN; AMSACRINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVENT FREE SURVIVAL; HIGH RISK PATIENT; HUMAN; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 71749113033     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.10.003     Document Type: Review

References (27)

1. Freireich E.J. Arabinosyl cytosine: a 20-year update. J Clin Oncol 5 (1987) 523-524
2. Coltman Jr. C.A., Freireich E.J., Pendleton O., et al. Adult acute leukemia studies utilizing cytarabine: early Southwest Oncology Group trials. Med Pediatr Oncol 10 Suppl. 1 (1982) 173-183
3. Weil M., Glidewell O.J., Jacquillat C., et al. Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res 33 (1973) 921-928
4. Preisler H.D., Rustum Y., Henderson E.S., et al. Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood 53 (1979) 455-464
5. Keating M.J., Smith T.L., McCredie K.B., et al. A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 47 (1981) 2779-2788
6. Rai K.R., Holland J.F., Glidewell O.J., et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 58 (1981) 1203-1212
7. Preisler H., Davis R.B., Kirshner J., et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood 69 (1987) 1441-1449
8. Vogler W.R., Velez-Garcia E., Weiner R.S., et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 10 (1992) 1103-1111
9. Wiernik P.H., Banks P.L., Case Jr. D.C., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79 (1992) 313-319
10. Berman E., Heller G., Santorsa J., et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77 (1991) 1666-1674
11. Mandelli F., Petti M.C., Ardia A., et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. Eur J Cancer 27 (1991) 750-755
12. Arlin Z., Case Jr. D.C., Moore J., et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 4 (1990) 177-183
13. Hansen O.P., Pedersen-Bjergaard J., Ellegaard J., et al. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark. Leukemia 5 (1991) 510-516
14. Berman E., Arlin Z.A., Gaynor J., et al. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Leukemia 3 (1989) 115-121
15. Hewlett J., Kopecky K.J., Head D., et al. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study. Leukemia 9 (1995) 562-569
16. Weick J.K., Kopecky K.J., Appelbaum F.R., et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 88 (1996) 2841-2851
17. Rowe J.M., Andersen J.W., Mazza J.J., et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86 (1995) 457-462
18. Rowe J.M., Neuberg D., Friedenberg W., et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103 (2004) 479-485
19. Cassileth P.A., Lynch E., Hines J.D., et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79 (1992) 1924-1930
20. Cassileth P.A., Harrington D.P., Appelbaum F.R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339 (1998) 1649-1656
21. Rowe J.M., and Tallman M.S. Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged?. Blood 90 (1997) 2121-2126
22. Kolitz J.E., George S.L., Dodge R.K., et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 22 (2004) 4290-4301
23. Castaigne S., Chevret S., Archimbaud E., et al. Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 104 (2004) 2467-2474
24. Fernandez H.F., Sun Z., Yao X., et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361 (2009) 1249-1259 Copyright 2009 Massachusetts Medical Society. All rights reserved
25. Lowenberg B., Ossenkoppele G.J., van P.W., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361 (2009) 1235-1248
26. Burnett A.K., Kell W.J., Goldstone A.H., et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease-free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. Blood 108 (2006) 8a (abstr 13)
27. Rowe J.M., and Tallman M.S. Therapy for acute myeloid leukemia. In: Hoffman R., Furie B., McGlave P., Silberstein L.E., Shattil S.J., Benz Jr. E.J., and Heslop H. (Eds). Hematology: basic principles and practice (2009), Churcill Livingstone, Philadelphia 965-989